IP portfolio

20 assets across one regenerative platform

Production • In-vivo microenvironment • Delivery • Monitoring

Portfolio at a glance

A concise view of the estate

The portfolio is best understood as a connected system rather than a list of isolated filings.

Total IP assets

Across granted or in-force, pending, and in-preparation positions

Granted or in force

14 invention patents, including restored RU 2715313, two utility models, and one industrial design

Pending applications

Applications progressing through examination

In preparation

The next asset in the portfolio development pipeline

4 technology layersProduction, microenvironment, delivery, and monitoring

3 product categoriesEquipment, biologics, and services

6 near-term programsClinical applications drawing primarily on Layers 1–3

Jurisdiction. All granted and pending rights in the estate are registered in the Russian Federation. International protection is a funded workstream of the current financing and will be pursued through eligible PCT, national, regional, and improvement filings only where rights remain available; expired priority families are not treated as recoverable, and know-how is retained as trade secrets where appropriate. Freedom-to-operate and claim-scope review is in progress; no claim of uniqueness is made until that work is complete.

Technology-to-product map

Where the IP sits in the bigger picture

The estate protects connected capabilities across the regenerative value chain and supports multiple commercial outputs from the same technical foundation.

Platform layer	Technology position	Portfolio position	Commercial outputs
Production	Aerosol bioreactor, cellular spheroids, Organ Building Blocks, and GMP-compatible production workflows	Granted and pending assets	Bioreactor systems, OBBs, cellular spheroids, media, and consumables
Microenvironment	In-vivo bioreactor creating a controlled local environment at the injury site	Granted, restored, and pending assets	Regeneratron device and indication-specific applications
Delivery	Minimally invasive placement of biologics, with integration into third-party and partner bioprinting systems	Granted and pending assets	Delivery kits, integration protocols, workflows, and training
Monitoring	Digital twin, sensors, and potential closed-loop adaptive delivery	Proprietary know-how with future filings planned	Patient-journey software and monitoring services

The platform value chain

Production equipment Biologics Delivery into the patient In-vivo microenvironment Regenerated tissue Monitoring and digital twin Restoration of normal anatomy

Portfolio update

Rights granted since December 2025

Six rights have been granted since December 2025. Four of them—RU 2862285, RU 2862804, RU 153286, and RU 244635—moved from pending to granted during this period, bringing the estate to 17 granted or in-force IP rights as of July 2026.

Granted right	Type	Grant date	Subject and application
RU 2860621 C1	Invention patent	21 Apr 2026	Bioreactor for stimulating fingertip regeneration or treating a human finger wound. App. 2025125825; filed 19 Sep 2025.
RU 2862285 C1	Invention patent	19 May 2026	Cell therapy for focal alopecia and a cellular spheroid for treating focal alopecia. App. 2025131595; filed 13 Nov 2025.
RU 2862804 C1	Invention patent	26 May 2026	Reparative osteogenesis during distraction osteosynthesis using cellular spheroids. App. 2025125573; filed 17 Sep 2025.
RU 239614 U1	Utility model	11 Dec 2025	Nutrient-medium supply device for the mesh-nebulizer spray chamber of a tissue-engineering bioreactor. App. 2025126575; filed 29 Sep 2025.
RU 153286	Industrial design	4 Jun 2026	Tissue-engineering bioreactor. App. 2025504429; filed 11 Aug 2025.
RU 244635	Utility model	7 Jul 2026	Device for securing surgical sutures in a tissue-engineering bioreactor. App. 2026106767; filed 14 Mar 2026.

Current filing pipeline

Position	Status	Subject
Application 2026105201	Pending · filed 26 Feb 2026	Tissue-engineered construct, implant, and kit
Application 2025506198	Pending · filed 17 Nov 2025	In-vivo fingertip bioreactor
Next filing	In preparation with the Skolkovo IP Centre	Methods for treating stroke, traumatic brain injury, and cerebral palsy

Commercial reach

Three product categories from one IP foundation

Category 1

Equipment

Aerosol bioreactors, the Regeneratron in-vivo bioreactor, delivery kits, and partner-system integration.

Category 2

Biologics

Cellular spheroids, Organ Building Blocks, and indication-specific cell-therapy products.

Category 3

Services

Protocols, training, licensing, consumables, and longer-horizon monitoring services.

Ownership & development

Consolidation and international development

The estate is held of record by RAZIN JSC, a founder-controlled Russian company, and is intended for assignment to Regentron FZE at financing closing. Because the founder controls both entities, the assignment is a transfer under common control, subject to independent confirmation of title, inventorship, employer rights, and encumbrances.

Portfolio foundation

20 assets across the platform
17 granted or in-force IP rights
Two pending applications
One asset in preparation

Current IP program

Title verification and assignment recordal
Freedom-to-operate and claim-scope work
Eligible international filings
Continuing improvement filings and portfolio development

The complete asset schedule, including patent numbers, status, priority dates, and filing actions, is available to qualified counterparties under NDA.